Literature DB >> 29615336

Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of non-small cell lung cancer.

James M Isbell1, David R Jones2, Bob T Li3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29615336     DOI: 10.1016/j.jtcvs.2017.12.157

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


× No keyword cloud information.
  5 in total

1.  Analysis of circulating tumor DNA: The next paradigm shift in detection and treatment of lung cancer.

Authors:  David S Schrump; Julie A Hong
Journal:  J Thorac Cardiovasc Surg       Date:  2018-02-08       Impact factor: 5.209

2.  Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons.

Authors:  David R Jones; Yi-Long Wu; Masahiro Tsuboi; Roy S Herbst
Journal:  J Thorac Cardiovasc Surg       Date:  2021-02-09       Impact factor: 6.439

3.  Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in nonsmall-cell lung cancer.

Authors:  Wenfeng Fang; Yuxiang Ma; Jiani C Yin; Huaqiang Zhou; Fufeng Wang; Hua Bao; Ao Wang; Xue Wu; Shaodong Hong; Yunpeng Yang; Yan Huang; Hongyun Zhao; Yang W Shao; Li Zhang
Journal:  Clin Transl Med       Date:  2020-01

4.  Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer.

Authors:  Min Zhang; Chao Huang; Huan Zhou; Dan Liu; Runze Chen; Xiuhua Li; Ye Cheng; Bing Gao; Jun Chen
Journal:  Thorac Cancer       Date:  2021-11-18       Impact factor: 3.500

Review 5.  Graphene-based biosensors for the detection of prostate cancer protein biomarkers: a review.

Authors:  Li Xu; Yanli Wen; Santosh Pandit; Venkata R S S Mokkapati; Ivan Mijakovic; Yan Li; Min Ding; Shuzhen Ren; Wen Li; Gang Liu
Journal:  BMC Chem       Date:  2019-09-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.